EGFL7-binding peptides for anti-angiogenesis therapy and imaging
- Summary
- Over-expression of EGFL7 in many cancer types correlates with increased metastasis and poor prognosis. As a tumor grows beyond 1mm it recruits new blood vessels through the process of angiogenesis, suppressing this process to prevent further tumor growth and metastasis is a promising therapeutic strategy for cancer.
很多癌症的EGFL7过度表达与转移加剧和预后不良有关。肿瘤生长超过1毫米以后，就会通过血管生成方法形成新生血管，获得营养支持，通过抑制血管生成过程来防止肿瘤的继续生长和转移是很有潜力的癌症治疗策略。
A suite of 9 novel peptides has been developed that specifically target and bind with high affinity to EGFL7 to inhibit its activity. The peptides have demonstrated significant anti-angiogenic activity by dramatically inhibiting human endothelial cell sprouting and tube formation and the formation of tumor induced new blood vessels both in vitro and in vivo (mice).
本公司开发的一系列9个新型肽能精确定位EGFL7，以很高的亲和力结合EGFL7，抑制EGFL7的活性。这些肽能极大地抑制人血管内皮细胞形成和血管形成，以及体外和体内（大鼠）肿瘤诱导新血管的形成，具有很强的抗血管形成活性。
Potent in vivo angiogenesis inhibitors
有效的体内血管形成抑制剂
Novel composition of matter high affinity peptides with optimized serum half-life
提高血清半衰期的高亲和力肽的新型物质组成
Potential combination anti-angiogenesis therapy with VEGF inhibitors
结合抗血管生成治疗与VEGF抑制剂的可能性
Incorporation of the peptides on clinical nanoparticles can target drugs to sites of pathological angiogenesis
在临床纳米颗粒上结合肽能使药物精确定位病理性的血管生成部位
Potent in vivo angiogenesis inhibitors useful for treatment of cancer, diabetic retinopathy, wet AMD
有效的体内血管生成抑制剂，可用于癌症、视网膜病变、湿性老年黄斑病变治疗
Gallium-68 labeled peptides efficiently image angiogenesis for research or clinical applications
镓68标记多肽在研究或临床应用中有效形成血管生成图像
- Technology Application
- 其它
- Detailed Technology Description
- Ready for animal model test
准备进入动物模型试验阶段
- Type of Cooperation
- 技术售让
- Coverage Areas
- 生物技术/制药/医疗
- Goods and Services
- 制药行业
For more information, please click Here
